Using IMPrESS to guide policy change in multiple sclerosis

Abstract

The International MultiPlE Sclerosis Study (IMPrESS) studied the significant impact of multiple sclerosis (MS) on the health and well-being of both people with the disease and their caregivers, along with its broader socioeconomic impact. Results confirmed that there is an urgent need to achieve better outcomes for people with MS. This paper uses results from the IMPrESS to present new international evidence on the socioeconomic burden of MS and discuss the merits of a likely paradigm shift in the management of MS towards the use of better (and more accurate) diagnostic follow-up to monitor disease progression and the earlier use of disease-modifying treatments (DMTs) to achieve better clinical, quality-of-life and socioeconomic results for individuals.

Keywords

Multiple sclerosis early treatment economic burden quality of life health technology assessment unmet needs

Get full access to this article

View all access options for this article.

References

Giovannoni

Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis – yes. Mult Scler 2015; 21: 134–136.

Banwell

Giovannoni

Hawkes

et al . Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord 2013; 2: 65–67.

Giovannoni

Butzkueven

Dhib-Jalbut

et al . Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9: S5–S48.

Kanavos

Tinelli

Efthymiadou

et al . Towards better outcomes in multiple sclerosis by addressing policy change: The International MultiPlE Sclerosis Study (IMPrESS). The London School of Economics and Political Science, March 2016.

Ernstsson

Gyllensten

Alexanderson

et al . Cost of illness of multiple sclerosis: A systematic review. PLoS ONE 2016; 11: e0159129.

Kobelt

Thompson

Berg

et al . New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23: 1123–1136.

Marrie

Elliott

Marriott

et al . Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83: 929–937.

Holloway

Redford-Totts

Right treatment, right time?

How people with MS make decisions about disease modifying drugs MS Society, 2014, http://www.treatmerightms.org.uk/wp-content/uploads/2014/04/Right-treatment-right-time.pdf

Stephens

Handkle

Doshi

et al . International survey of methods used in health technology assessment (HTA): Does practice meet the principles proposed for good research? Comp Eff Res 2012; 2: 29–44, https://www.ispor.org/workpaper/International-survey-of-methods-used-in-HTA.pdf

10.

Lublin

Reingold

Cohen

et al . Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB